Abstract:Abstract Melanoma is an aggressive type of cutaneous malignancy. Although the inhibitors targeting BRAF and/or MEK pathways provide a therapeutic option for non-resectable melanoma driven by BRAF mutation, melanoma, especially metastatic melanoma, has still become one of the most threatening malignancies. Thus, identifying the exact molecular mechanisms involved in melanoma growth and discovering the novel targets for melanoma therapy is urgently needed. In this study, we screened a siRNA library targeting 6024 human genes in human melanoma cells and identified KMT2A as a potential therapeutic target for melanoma. KMT2A was highly expressed in melanoma cell lines and tumor tissues of melanoma patients. Knockdown of KMT2A by siRNA or shRNA significantly inhibited cell viability and colony formation, whereas exogenous expression of KMT2A effectively promoted cell growth in various melanoma cell lines. Further mechanism studies showed that the KMT2A-mediated regulation of melanoma growth was through targeting the hTERT and CBP signaling. Knockdown of KMT2A significantly inhibited hTERT promoter activity and protein expression and attenuated telomerase activity. Overexpression of hTERT rescued the KMT2A knockdown-mediated melanoma cell growth. By contrast, exogenous expression of KMT2A activated hTERT transcription and expression and increased telomerase activity in melanoma cells. Moreover, we found that KMT2A promoted hTERT expression and melanoma cell growth by cooperating with the transcriptional co-activator CBP, which interacted with and acetylated KMT2A. Inhibition of CBP by siRNA or a CBP-specific inhibitor suppressed the acetylation of KMT2A, abrogated the binding of KMT2A on the hTERT promoter and down-regulated hTERT expression, thereby inhibiting the growth of melanoma cells. Conversely, overexpression of CBP increased KMT2A acetylation and the binding to hTERT promoter, resulting in the promotion of hTERT expression and cell growth. The in vivo studies also showed that KMT2A promoted melanoma growth by activating the hTERT signaling in a xenograft tumor mouse model. Furthermore, the analyses for the clinical samples demonstrated that KMT2A expression was positively correlated with hTERT in tumor tissues of melanoma patients, and the high expression of both KMT2A and hTERT was associated with the worse clinical TNM staging and poor prognosis in melanoma patients. Taken together, our results indicate that KMT2A promotes melanoma growth by activating hTERT and CBP signaling in human melanoma. Our study therefore provides new insights into understanding the regulatory mechanism of melanoma growth and suggests that the KMT2A/CBP/hTERT signaling may be a potential therapeutic target for human melanoma. Funding support: This work was supported by the funds from the National Natural Science Foundation of China (81071687, 81272195), the State “973 Program” of China (2014CB542005). Citation Format: Changlin Zhang, Ranran Tang, Kefang Zhang, Wenlin Huang, Wuguo Deng. KMT2A promotes tumor growth by activating hTERT and CBP signaling and predicts poor prognosis in human melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 374. doi:10.1158/1538-7445.AM2017-374

UBTF facilitates melanoma progression via modulating MEK1/2-ERK1/2 signalling pathways by promoting GIT1 transcription

Upregulation of UHRF1 Promotes the Progression of Melanoma by Inducing Cell Proliferation

The oncogenic function and potential mechanism of basic transcription factor 3 in melanoma

The ubiquitin-like protein UBTD1 promotes colorectal cancer progression by stabilizing c-Myc to upregulate glycolysis

Tumour suppressor candidate 3 inhibits biological function and increases endoplasmic reticulum stress of melanoma cells WM451 by regulating AKT/GSK3‐β/β‐catenin pathway

Protein tyrosine phosphatase 1B(PTP1B) promotes melanoma cells progression through Src activation

UBE2T promotes glioblastoma invasion and migration via stabilizing GRP78 and regulating EMT

AKT-mediated regulation of chromatin ubiquitylation and tumorigenesis through Mel18 phosphorylation

796 the Up-Regulated Ubiquitin Ligase TNFAIP3 Plays an Oncogenic Role in Melanoma

BTF3 promotes proliferation and glycolysis in hepatocellular carcinoma by regulating GLUT1

UBE2T Promotes Glioblastoma Malignancy Through Ubiquitination‐mediated Degradation of RPL6

YY1 cooperates with TFEB to regulate autophagy and lysosomal biogenesis in melanoma.

Oncogenic DNA methyltransferase 1 activates the PI3K/AKT/mTOR signalling by blocking the binding of HSPB8 and BAG3 in melanoma

Kmt2a Promotes Tumor Growth By Activating Htert And Cbp Signaling And Predicts Poor Prognosis In Human Melanoma

Ubiquitination-related regulator UBTD1 closely associated with Immune Escape and suppressed cells ferroptosis in Colorectal Carcinogenesis

Disruption of LTBP4 Inhibition-Induced TGFβ1 Activation Promoted Cell Proliferation and Metastasis in Skin Melanoma by Inhibiting the Activation of the Hippo-YAP1 Signaling Pathway

RUVBL1-modulated Chromatin Remodeling Alters the Transcriptional Activity of Oncogenic CTNNB1 in Uveal Melanoma

TMBIM1 Promotes EMT by Stimulating Autophagic Degradation of E-cadherin Via AMPK/mTOR/ULK1 Axis in Human Gliomas

Ubiquitination in melanoma pathogenesis and treatment

Study on the correlation between the expression of basic transcription factor 3 (BTF3) and the efficacy and prognosis of patients with malignant melanoma (MM).

Bioinformatics-based Analysis Reveals Elevated MFSD12 As a Key Promoter of Cell Proliferation and a Potential Therapeutic Target in Melanoma.